Analysis

In the face of uncertainty

A challenging future for biopharmaceutical innovation

The time, cost, risk, and complexity associated with biopharmaceutical innovation has reached a point where the current drug development process may not be sustainable over the longer term. It is possible that the most attractive solution may require a fundamentally different approach for delivering innovative products.

In the face of uncertainty: A challenging future for biopharmaceutical innovation

Download PDF

Learn more about biopharmaceutical innovation

The biopharma industry is in a precarious position regarding innovation: big bets in bold new areas are fraught with complexity & uncertainty, while success in mature therapeutic areas is becoming increasingly challenging. Sustaining innovation has consistently been difficult, but the resulting benefit to patients has generally provided innovators with an ROI sufficient enough to compensate for the risk. The balance of this equation is shifting and appears to be getting even tougher for innovators and investors. A recent Deloitte study has shown that the overall rate of return on R&D investment for the 12 largest biopharmaceutical firms has dropped significantly since 2010, and the cost of developing a new medicine has risen substantially.

Meet the author

Greg Reh

Greg Reh

US Sector Leader | Life Sciences

Greg is a principal with Deloitte Consulting where...More

Contact us

Contact us via our online form

Submit RFP

Submit via our online form

Find an office

Find a local office

People

Matthew Hudes

Principal | U.S. Managing Principal, Biotechnology

People

Ralph Marcello

Life Sciences | Strategy & Operations

People

Dan Ressler

R&D Practice Leader | Life Sciences